Can a Decades-Old drug reverse pancreatic scarring?

NCT ID NCT05551858

Ongoing Disease control Sponsor: Georgetown University Source: ClinicalTrials.gov ↗

First seen Aug 05, 2026 · Last updated Aug 06, 2026 · Updated 1 time

Summary

This trial tests whether proglumide, an older drug that blocks a specific receptor, can safely reduce pain and slow or reverse the scarring seen in chronic pancreatitis. The study includes adults with confirmed chronic pancreatitis and compares proglumide against a placebo over 12 to 24 weeks. Researchers are checking safety, pain levels, and how well the pancreas functions.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: proglumide (an oral drug that blocks the CCK-B receptor)
What this could lead to: If successful, this could lead to a new treatment that reduces pain and may slow or reverse pancreatic damage in chronic pancreatitis, potentially lowering cancer risk.
What could go wrong: This is an early-phase trial with a small number of participants, so results may not hold up in larger studies. The drug's safety and effectiveness are still unproven, and it may not work as hoped.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CHRONIC PANCREATITIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

chronic pancreatitis diabetes mellitus Pain pancreatitis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PAIN PANCREAS FIBROSIS SAFETY ISSUES

Contacts and locations

Locations

Georgetown University

Washington D.C., District of Columbia, 20007, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.